Clinical Cancer Research Versailles No Abst Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bernal, R. M.
Right arrow Articles by Batra, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bernal, R. M.
Right arrow Articles by Batra, R. K.
Clinical Cancer Research Vol. 8, 1915-1923, June 2002
© 2002 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Soluble Coxsackievirus Adenovirus Receptor Is a Putative Inhibitor of Adenoviral Gene Transfer in the Tumor Milieu1

Ray M. Bernal, Sherven Sharma, Brian K. Gardner, Joanne T. Douglas, Jeffrey M. Bergelson, Steven M. Dubinett and Raj K. Batra2

Department of Medicine and The University of California at Los Angeles (UCLA)/ Wadsworth Pulmonary Immunology and Gene Medicine Laboratory [R. M. B., S. S., B. K. G., S. M. D., R. K. B.], and Jonsson Comprehensive Cancer Center [S. M. D., R. K. B.], UCLA and Veterans Administration-Greater Los Angeles Health Care System, Los Angeles, California 90073; Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery and the Gene Therapy Center, University of Alabama at Birmingham, Birmingham, Alabama 35222 [J. T. D.]; and Division of Immunologic and Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 [J. M. B.]

Purpose: Several barriers that collectively restrict gene delivery by viral vectors in vivo have been described. Previously, we identified soluble chondroitin sulfate-proteoglycans/glycosaminoglycans in malignant pleural effusions (MPEs) as inhibitors of retroviral vector transduction. Soluble components of MPE also inhibited adenoviral (Ad) gene transfer, and the factors were characteristically filterable, titrable, stable at 56° C, and blocked the binding of Ad to target cells. Depleting immunoglobulin from MPE, partially reversed the block to Ad transduction, instigating a search for additional factors that bound Ad in MPE.

Experimental design: Vector-protein interactions were identified after the resolution of MPE-components by SDS-PAGE. Viral overlays and immunoblots delineated significant interactions, and the potential relevance of those interactions was tested in transduction efficiency bioassays.

Results: Immunoglobulin is the predominant factor inhibiting Ad gene transfer in MPE. Albumin also interacted with Ad, although at predicted serum concentrations, it did not effect Ad transduction efficiency in vitro. Soluble coxsackievirus-Ad receptor (sCAR) was then identified in MPE. In a survey of 18 MPE, the mean concentration of sCAR was variable and estimated to be 3.51 ± 5.02 ng/ml by ELISA. The impact of sCAR on transduction efficiency in this milieu was next assessed. Whereas immunodepletion of sCAR from MPE by affinity chromatography resulted in enhanced gene transfer within MPE, the inhibition of adenoviral gene transfer was not evident when the predicted concentrations of recombinant sCAR were added into the transduction medium.

Conclusions: These studies indicate that, in addition to anti-Ad antibodies, other specific and nonspecific factors interact with viral vectors and may impair gene transfer in the tumor milieu. The presence of sCAR in MPE puts forward the notion that in certain contexts (e.g., within the extracellular matrix of solid tumors) the concentrations of secreted (or shed) CAR may be high enough to effectively compete with Ad gene delivery.




This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
M. Qin, B. Escuadro, S. Sharma, and R. K. Batra
Gene Transfer Mediated by Native versus Fibroblast Growth Factor-Retargeted Adenoviral Vectors into Lung Cancer Cells
Am. J. Respir. Cell Mol. Biol., March 1, 2005; 32(3): 211 - 217.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Dorner, D. Xiong, K. Couch, T. Yajima, and K. U. Knowlton
Alternatively Spliced Soluble Coxsackie-adenovirus Receptors Inhibit Coxsackievirus Infection
J. Biol. Chem., April 30, 2004; 279(18): 18497 - 18503.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Qin, S. Chen, T. Yu, B. Escuadro, S. Sharma, and R. K. Batra
Coxsackievirus Adenovirus Receptor Expression Predicts the Efficiency of Adenoviral Gene Transfer into Non-Small Cell Lung Cancer Xenografts
Clin. Cancer Res., October 15, 2003; 9(13): 4992 - 4999.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.